What Is Semaglutide? Everything You Need to Know

What Is Semaglutide?

Semaglutide is a prescription medication that belongs to a class of drugs called GLP-1 receptor agonists. Originally developed for type 2 diabetes management, it gained widespread attention after clinical trials showed significant weight loss results in patients who used it alongside lifestyle changes.

The medication works by mimicking a naturally occurring hormone in your body called glucagon-like peptide-1 (GLP-1). This hormone plays a central role in regulating appetite, blood sugar levels, and how your body processes food. When you take semaglutide, you're essentially amplifying signals your body already uses to manage hunger and metabolism.

Semaglutide is available as both an injection and, more recently, in oral form. The injectable version is typically administered once per week, making it a convenient option compared to daily medications.

How Semaglutide Works in Your Body

When you eat a meal, your gut naturally releases GLP-1 to signal fullness to your brain. Semaglutide mimics this process but with a much longer duration of action. While natural GLP-1 breaks down within minutes, semaglutide stays active for about a week due to its modified molecular structure.

The medication acts on three key areas. First, it slows gastric emptying, meaning food stays in your stomach longer and you feel full for extended periods. Second, it works directly on appetite centers in the brain, particularly the hypothalamus, reducing cravings and the urge to eat between meals. Third, it improves how your body responds to insulin, which helps regulate blood sugar levels.

Most patients begin to notice reduced appetite within the first two to three weeks. Weight loss typically becomes noticeable around weeks four through eight, with the most significant results appearing over several months of consistent use.

FDA Approval and Clinical Evidence

The FDA first approved semaglutide for type 2 diabetes in 2017 under the brand name Ozempic. In 2021, a higher-dose formulation was approved specifically for chronic weight management under the brand name Wegovy. This approval was based on extensive clinical trial data involving thousands of participants.

The landmark STEP trials studied semaglutide at a 2.4 mg weekly dose in over 4,500 adults. Participants who received semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Nearly one-third of participants lost more than 20% of their starting weight.

These results were considered groundbreaking in obesity medicine, as few previous medications had demonstrated this level of efficacy with an acceptable safety profile. Follow-up studies have continued to show durable results when patients stay on the medication.

Benefits Beyond Weight Loss

While weight loss is the most visible benefit, semaglutide has shown positive effects across several health markers. Clinical data shows improvements in blood pressure, cholesterol levels, and inflammatory markers. Many patients also report better energy levels, improved sleep quality, and a healthier relationship with food.

The SELECT trial, published in 2023, demonstrated that semaglutide reduced the risk of major cardiovascular events by 20% in overweight adults with established heart disease. This was a significant finding because it showed benefits that went well beyond the scale.

Patients also frequently report improvements in joint pain, mobility, and overall quality of life as they lose weight. For those with prediabetes, semaglutide has been shown to reduce the progression to full type 2 diabetes significantly.

Common Side Effects and How to Manage Them

Like all medications, semaglutide can cause side effects. The most common ones are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be most pronounced during the first few weeks and during dose increases, then typically fade as your body adjusts.

Starting at a low dose and gradually increasing over several weeks is the standard approach for minimizing side effects. Eating smaller meals, avoiding high-fat or very rich foods, and staying well-hydrated can also help. Most patients find that side effects become manageable or resolve entirely within the first month or two.

Serious side effects are rare but important to know about. These include pancreatitis, gallbladder problems, and, in very rare cases, thyroid tumors (observed in animal studies). Your prescribing physician will review your medical history to ensure semaglutide is safe for you.

Who Qualifies for Semaglutide Treatment?

Semaglutide for weight management is generally prescribed to adults with a BMI of 30 or higher (obesity) or a BMI of 27 or higher (overweight) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

It is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or those with Multiple Endocrine Neoplasia syndrome type 2. Pregnant or breastfeeding individuals should also avoid this medication. Your doctor will conduct a thorough evaluation before prescribing.

Getting Started with INA

At INA, the process begins with a simple online consultation. You'll complete a health questionnaire and connect with one of our licensed physicians who will review your medical history, discuss your goals, and determine if semaglutide is the right fit for you.

If approved, your medication ships directly to your door with clear instructions and ongoing support from your care team. We use a gradual dosing schedule to help minimize side effects and maximize your comfort. Your physician is available for check-ins and adjustments throughout your treatment journey.

Many patients find that starting with our GLP-1 Microdose option helps them ease into treatment with fewer initial side effects, before transitioning to a standard dose as their body adjusts.